List of Medicines for Brand Consideration (LMBC)
The List of Medicines for Brand Consideration includes medicines prescribers should consider prescribing by brand name as well as active ingredient name.
This document was last updated by the Commission in December 2022. From 1 January 2023, the Australian Government Department of Health and Aged Care is managing the curation of Active ingredient prescribing resources. From this date, please direct all AIP enquiries to firstname.lastname@example.org
Accessibility - We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.
Copyright - Unless stated otherwise, materials provided are covered by a Creative Commons Attribution-Non-Commercial-Share Alike (BY-NC-ND) 4.0 International License.
This List of Medicines for Brand Consideration includes medicines prescribers should consider prescribing by brand name as well as active ingredient name, if clinically necessary for the treatment of their patient. For example, if formulations of the same active ingredient and strength are not interchangeable due to variations in delivery of the active ingredient, prescribers should consider specification by brand for patient safety.